A

lexion Pharmaceuticals, until recently seen as one of biotech’s biggest success stories, is eliminating roughly 600 jobs and moving its headquarters to Boston amid federal investigations and pressure to cut costs.

The company made its name on Soliris, a treatment for rare diseases that — at a cost of about $700,000 a year — is also the world’s most expensive drug. But after a series of pipeline disappointments and an ill-advised $8.4 billion acquisition, Alexion is facing an uncertain future.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.